Akari Therapeutics提交关键专利申请,并公布靶向CEACAM5表达实体瘤的第二款ADC项目Aktx-102

美股速递
Jan 26

Akari Therapeutics PLC已正式提交一项关键专利申请,并同时揭晓其第二款抗体偶联药物(ADC)项目——Aktx-102。该创新疗法旨在精准靶向表达CEACAM5的实体瘤,为相关癌症治疗开辟新的路径。

此次专利布局与研发进展的公布,标志着公司在ADC领域迈出重要一步,有望进一步拓展其肿瘤治疗产品管线。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10